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ttp://dx.doi.org/10.1016/j.ajpath.2013.01.018Much fewer mice lacking androgen receptor (AR) in the entire body develop bladder cancer (BCa). However,
the role of urothelial AR (Uro-AR) in BCa development remains unclear. In the present study, we generated
mice that lacked only Uro-AR (Uro-AR/y) to develop BCa by using the carcinogen BBN [N-butyl-N-(4-
hydroxybutyl)-nitrosamine] and found that Uro-AR/y mice had a lower incidence of BCa and a higher
survival rate than did their wild-type (WT; Uro-ARþ/y) littermates. In vitro assay also demonstrated that Uro-
AR facilitates the neoplastic transformation of normal urothelial cells to carcinoma. IHC staining exhibited
less DNA damage, withmuch higher expression of p53 and its downstream target protein PNCA in Uro-AR/y
than that found in WT urothelium, which suggests that Uro-AR may modulate bladder tumorigenesis
through p53-PCNA DNA repair signaling. Indeed, Uro-AR/y mice with the transgene, simian vacuolating
virus 40 T (SV40T), in the urothelium (Uro-SV40T-AR/y) had a similar incidence of BCa as did their WT
littermates (Uro-SV40T-ARþ/y), and p53 was inactivated by SV40T in both genotypes. Use of the AR
degradation enhancer ASC-J9 led to suppression of bladder tumorigenesis, with few adverse effects in the
BBN-induced BCamouse model. Together, these results provide the ﬁrst direct in vivo evidence that Uro-AR
has an important role in promoting bladder tumorigenesis and BCa progression. Targeting AR with ASC-J9
may provide a novel approach to suppress BCa initiation. (Am J Pathol 2013, 182: 1811e1820; http://
dx.doi.org/10.1016/j.ajpath.2013.01.018)Supported by NIH grants CA122840 and CA127300 (C.C.), the George
H. Whipple Professorship Endowment, the National Science Council, the
Taiwan Department of Health Clinical Trial, and a Research Center of
Excellence grant (DOH99-TD-B-111-004) from China Medical University,
Taichung, Taiwan.
Disclosures: ASC-J9 was patented by the University of Rochester, the
University of North Carolina, and AndroScience Corp. and was licensed to
AndroScience Corp. Both the University of Rochester and C.C. receive
royalties from and own equity in AndroScience Corp.In the United States, bladder cancer (BCa) is the fourth leading
cancer in men and the eleventh in women.1 In men, the
incidence of BCa is approximately threefold higher than
in women, which suggests that sex hormone signals may
contribute to bladder tumorigenesis; however, detailed mech-
anisms remain unclear.
Expression of androgen receptor (AR) has been well
studied and has been detected in both benign urothelium2e4
and BCa2e10 via immunohistochemistry (IHC). However,
the reported range of AR expression in human benign uro-
thelium and BCa varies considerably among reports, from
0% to 86% and from 0% to 78%, respectively.2e5,7e10 The
huge variation in AR expression among reports may be due to
different methods of tissue preparation (eg, tissue processing
and embedding in parafﬁn) and staining (eg, antibody,
staining protocol, and criteria for positivity).11 Most reports
have suggested a higher level of AR expression in BCa thanstigative Pathology.
.in benign urothelium; however, some reports have reached
the opposite conclusion. Therefore, the correlation between
AR expression and BCa remains controversial.
Two animal models that target androgen-AR signals in
BCa, ie, castrated and AR knockout (ARKO) mouse models,
have provided evidence for the roles of androgen-AR
signaling in cancer development with distinct mechanistic
explanations. Using ARKO mice, Miyamoto et al12 reported
Hsu et althat the loss of AR in the entire body led to a reduced inci-
dence of BBN-induced BCa, which suggests that AR might
promote bladder tumorigenesis. Others13,14 have found that
surgical castration and high-dose antiandrogen (ﬂutamide)
therapy reduced bladder tumorigenesis in rats. Imaoka et al14
have suggested that castration-induced down-regulation of
P450 CYP4B1, a key P450 enzyme that converts BBN
[N-butyl-N-(4-hydroxybutyl)-nitrosamine] to the carcinogen
BCPN [N-butyl-N-(3-carboxy-propyl)-nitrosamine], is the
primary mechanism. Therefore, it remains unclear whether
urothelial AR (Uro-AR) has any role in promoting bladder
tumorigenesis.
To answer this question and explore the possibility of tar-
geting Uro-AR as a therapeutic approach to BCa, we gener-
ated conditional Uro-ARKO mice (Uro-AR/y) that lacked
AR only in urothelium.We found that Uro-AR could promote
bladder tumorigenesis via modulation of p53-PCNA signals.
The AR degradation enhancer ASC-J9, which degrades
Uro-AR, can suppress bladder tumorigenesis.
Materials and Methods
Chemicals and Cell Line
Dihydrotestosterone and the carcinogen 3-methylcholanthrene
(MCA) were purchased from Sigma-Aldrich (St. Louis, MO),
and the p53 inhibitor piﬁthrin-a (PFT) fromEnzoLife Sciences,
Inc. (Farmingdale, NY). ASC-J9 was obtained from Andro-
ScienceCorp. (SanDiego, CA). A human normal urothelial cell
line, SV-HUC-1, was purchased from ATCC (Manassas, VA)
and maintained in F-12K medium (Kaighn’s modiﬁcation of
Ham’s F-12 medium) with 10% fetal bovine serum. A human
kidney epithelial cell line, 293T,waspurchased fromATCCand
maintained in Dulbecco’s modiﬁed Eagle’s medium (GIBCO
Corp., Grand Island, NY) with 10% fetal bovine serum.
Plasmids and Stable Cell Lines
To generate an AR overexpressive stable clone of the SV-
HUC-1 cell line, the lentivirus vectors pWPI-AR or pWPI-
control were co-transfected with pMD2.G and pAX2 into
293T cells. After 48 hours of transfection, the cultured
medium of 293T cells was harvested and mixed with fresh
F-12K culture medium (ratio, 1:1) and 8 mg/mL polybrene
(Millipore Corp., Billerica, MA), then incubated with SV-
HUC-1 cells for 24 hours. The viral-infected SV-HUC-1
cells contained green ﬂuorescent protein, and the SV-HUC-
AR or SV-HUC-vector stable cells were obtained via ﬂow
cytometry sorting.
Generation of Urothelial ARKO Mice and Induction of
BCa by BBN
All animal procedures were approved by the University
Committee on Animal Resources of the University of
Rochester and in accordwithNIHguidelines.MaleUro-ARKO1812(Uro-AR/y) mice were generated by mating uroplakin II pro-
moteredriven Cre (UPII-Cre) male mice15 with ﬂox-AR
female mice.16 After genotyping, offspring male mice were
subjected to BBN-induced BCa experiments. The protocol
for BBN-induced BCa was used, as in a previous study.12
Uro-AR/y and Uro-ARþ/y mice were given, ad libitum,
drinking water containing 0.05% BBN (TCI America, Inc.,
Portland, OR), which was prepared twice a week, and BBN
consumption was recorded. At age 6 weeks, mice were given
drinking water containing BBN for 12 weeks, and thereafter
were given water without BBN.Mice were sacriﬁced at age 20
or 30 weeks, and bladders were harvested and preserved in
parafﬁn for later histologic diagnosis and IHC.
Generation of Uro-ARKO Mice with Uroplakin
PromotereDriven SV40T Transgene
To generate Uro-ARKO mice with spontaneous BCa, we
ﬁrst mated UPII-Cre mice with UPII-SV40T mice,17 which
harbor SV40T in the urothelium, to induce BCa. After
genotyping, the male offspring with both UPII-Cre and
UPII-SV40T transgenes were chosen to mate with ﬂox-AR
female mice for generation of Uro-ARKO male mice with
UPII-SV40T (Uro-SV40T-AR/y). Mice were sacriﬁced at
15, 20, and 30 weeks of age. Urinary tract specimens were
harvested for later analysis, similarly as in the BBN-induced
BCa mouse model.
Neoplastic Transformation of SV-HUC-1 Cells
The protocol for neoplastic transformation of SV-HUC-1 was
used, as described in a previous study.18 In brief, 1  106
SV-HUC-1 cells were seeded in 100-mm culture dishes. After
seeding for 48 hours, the culture medium was replaced with
serum-free F12-K containing 1 nmol/L dihydrotestosterone
and 5 mg/mL carcinogen MCA, with or without the p53
inhibitor PFT, at 30 mmol/L, and incubated for 48 hours. After
the ﬁrst 24 hours of MCA exposure, 1% fetal bovine serum
was added to the medium. After 48 hours of MCA exposure,
themediumwas replacedwith 1% fetal bovine serumeF12-K,
and cells were cultured until conﬂuent and then subcultured
with 1:3 split ratio. After two additional MCA exposures as
above, the SV-HUC-1 cells were cultured for 6 weeks to
complete neoplastic transformation.
Western Blot Analysis
Western blot analysiswasperformed aspreviouslydescribed.19
In brief, 50 mg protein from each cell sample was resolved via
electrophoresis in 10% or 15% SDS-PAGE gels and
transferred to polyvinylidene diﬂuoride membrane (Millipore
Corp.). Speciﬁc proteins were detected using antibodies
against human AR (C-19; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), g-H2AX (Ser139; Upstate Biotechnology,
Inc., Lake Placid, NY), and b-actin (N-21; Santa Cruz
Biotechnology).ajp.amjpathol.org - The American Journal of Pathology
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Figure 1 Decreased BBN-induced bladder tumorigenesis in mice lacking
Uro-AR.A: Incidence of hematuria in Uro-ARþ/y (nZ 22) and Uro-AR/y (nZ
11) mice. Urine was collected from each mouse, and erythrocyte concentra-
tions were detected using test strips. Positive response indicates presence of
blood in the urine. Uro-ARþ/y mice showed a signiﬁcantly higher incidence of
hematuria than did Uro-AR/y mice at age 20 weeks under 12-week BBN
challenge. B: Incidence of BCa in Uro-ARþ/y (nZ 16) and Uro-AR/y (nZ 8)
mice. After 12 weeks of BBN treatment, Uro-ARþ/y and Uro-AR/y mice were
sacriﬁced at age20weeks, and bladderswereharvested, stainedwithH&E, and
diagnosed by licensed pathologists. Uro-ARþ/y mice revealed a signiﬁcantly
higher incidence of BCa than did Uro-AR/y mice (50% versus 0%). C: H&E
staining for morphologic features of benign and tumorous bladder. Left panel
is representative of normal bladder, and right panel is representative of BCa
(circled) in a Uro-ARþ/y mouse. For statistical analysis, differences in
hematuria and tumor incidence between the two groups were analyzed using
Fisher’s exact test. Original magniﬁcation, 400. Scale bars: 50 mm.
Urothelial AR Promotes BCa DevelopmentHistology and IHC
Bladders were ﬁxed in 10% buffered formalin (Sigma). After
standard tissue processing, bladder tissues were embedded in
parafﬁn. Tissue sections were treated with H&E for general
histologic evaluation.All histologic datawere diagnosedbyour
licensed pathologist (H.M.).We used the ABC kit andDAB kit
(both fromVectorLaboratories, Inc.,Burlingame,CA) to detect
AR, g-H2AX, p53, PCNA, and p21 using antibodies (from
Santa Cruz Biotechnology) speciﬁc for mouse AR (C-19),
g-H2AX (Ser139), p53 (FL-393), PCNA (FL-261), and p21
(F-5). The terminal deoxynucleotidyl transferaseemediated
TUNEL staining assay was performed using a Fluorescein-
FragELDNAFragmentationDetectionKit (CalbiochemCorp.,
La Jolla, CA). Cell proliferation and apoptotic index were
determined using the percentage of PCNA- and TUNEL-
positive cells in 100 cells from each specimen.
Suppression of Bladder Tumorigenesis in Mice via AR
Degradation Enhancer ASC-J9
The AR degradation enhancer ASC-J9 was used to examine
the suppression of bladder tumorigenesis induced by BBN.
Six-week-old FVB male mice were subjected to BBN
challenge for 12 weeks to induce BCa. When mice were
aged 16 weeks, they were divided into two groups, vehicle
control and ASC-J9, and subjected to daily treatment via i.p.
injection (75 mg/kg body weight). At age 24 weeks, mice
were sacriﬁced, and bladders were harvested for histologic
diagnosis.
Statistical Analysis
Differences in mean values between the two groups were
analyzed using the two-tailed Student’s t-test. Differences in
tumor incidence between the two groups were analyzed
using Fisher’s exact test. Difference in survival rate with
BCa between the two groups was analyzed using the log-
rank (Mantel-Cox) test. P < 0.05 was considered statisti-
cally signiﬁcant.
Results
Generation and Characterization of Mice Lacking
Uro-AR
To study the role of Uro-AR in bladder tumorigenesis, we
generated a new mouse model (Uro-AR/y) in which AR is
deleted only in urothelial cells by mating male UPII-Cre mice
with female ﬂox-AR mice. The detailed mating strategy is
described in Supplemental Figure S1A. The tail genotyping
results demonstrated that the new Uro-AR/y mice carried
all transgenes, such as UPII-Cre and ﬂox-AR allele
(Supplemental Figure S1B). IHC staining of the bladder from
wild-type (WT; Uro-ARþ/y) and Uro-AR/y mice using anti-
body against ARC-terminal showed that partial deletion of ARThe American Journal of Pathology - ajp.amjpathol.orgwas restricted to the urothelial cells and was not found in the
adjacent stromal cells (Supplemental Figure S1C). Further-
more, the serum testosterone levels were similar between
20-week-old Uro-AR/y mice and their WT littermates (PZ
0.479) (Supplemental Figure S1D), indicating that altered
phenotypes, including bladder tumorigenesis and animal
mortality, found in the Uro-AR/y mice were not due to the1813
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Figure 2 ARpromotes bladder tumorigenesis by facilitating theneoplastic
transformation of normal urothelial cells. A: mRNA expression of AR in the
stable cell line SV-HUC-1. mRNA samples were isolated from SV-HUC-V and SV-
HUC-AR stable cells and analyzed for expressive quantiﬁcation using real-time
PCR. SV-HUC-AR cells expressed higher ARmRNA levels thandid SV-HUC-V cells.
B: AR protein expression in SV-HUC-V and SV-HUC-AR cells. Western blot
analysis revealed that, compared with SV-HUC-V cells, SV-HUC-AR cells
expressed abundant AR protein. C: Colony formation of neoplastic transformed
SV-HUC-V and SV-HUC-AR cells in soft agar. After the carcinogen MCA induced
neoplastic transformation, the same number of SV-HUC-V and SV-HUC-AR cells
were seeded into soft agar for colony formation to examine the degree of
neoplastic transformation. SV-HUC-AR stable cells revealed signiﬁcantly more
colonies than did SV-HUC-V cells, which indicated that AR may promote
neoplastic transformation of normal urothelial cells. Difference in colony
formation numbers between the two groups was analyzed using the two-tailed
t-test. Results are expressed as the means SEM of three experiments.
Hsu et alchange in circulating testosterone. Furthermore, there was no
difference in consumption of drinking water containing BBN
between Uro-ARþ/y and Uro-AR/y male mice (P Z 0.304)
(Supplemental Figure S1E).
Decreased BBN-Induced Bladder Tumorigenesis in Mice
Lacking Uro-AR
To detect bladder tumorigenesis at the early stage, we ﬁrst
used a chemical reagent dipstick to monitor hematuria, as
described previously20,21 in the Uro-ARþ/y and Uro-AR/y
mice at age 20 weeks. There was a statistically signiﬁcant
difference in the detection of hematuria between Uro-ARþ/y
and Uro-AR/y mice (65% versus 19%; P Z 0.026)
(Figure 1A). We then examined bladder tumorigenesis in
Uro-ARþ/y and Uro-AR/y mice at age 20 weeks via histo-
logic diagnosis and found that 50% of Uro-ARþ/y mice had
noninvasive (stage pTa) urothelial carcinoma, whereas Uro-
AR/y male mice were all cancer free (Figure 1, B and C) (P
Z 0.022). These results suggested that Uro-AR was able to
promote BBN-induced bladder tumorigenesis.
AR Promotes Bladder Tumorigenesis by Facilitating
Neoplastic Transformation of Normal Urothelial Cells
We further conﬁrmed the role of Uro-AR in bladder tumor-
igenesis via a neoplastic transformation assay. We ﬁrst
established the human normal urothelial cell (SV-HUC-1)
lines with stable transfection of AR (SV-HUC-AR) and
vector control (SV-HUC-V). The mRNA and protein levels
of SV-HUC-AR and SV-HUC-V cells were examined using
real-time PCR andWestern blot analysis (Figure 2, A and B).
These stable cells were then subjected to neoplastic trans-
formation withMCA for induction of colonies in the soft agar
assay. The results showed that SV-HUC-AR cells form more
colonies in soft agar than do SV-HUC-V cells (Figure 2C),
which suggests that AR is able to promote neoplastic trans-
formation of normal urothelial cells. Together, results from
the in vivo BBN-induced bladder tumorigenesis mouse
model (Figure 1) and the in vitro neoplastic transformation
assay (Figure 2) indicated that Uro-AR was able to promote
bladder tumorigenesis.
Increased p53-PCNAeMediated DNA Damage Repairing
Signals in Urothelium in Mice Lacking Uro-AR
To dissect the mechanism(s) by which Uro-AR promotes
BBN-induced bladder tumorigenesis, weﬁrst examinedDNA
damage in benign urothelium from 20-week-old Uro-ARþ/y
and Uro-AR/y mice after treatment with BBN. IHC staining
with the DNA damage marker g-H2AX showed that Uro-
ARþ/y mice exhibited more g-H2AX signals in the benign
urothelium than did Uro-AR/y mice (Figure 3A). Similar
results were obtained in the urothelial cell line. SV-HUC-AR
expressed a higher level of g-H2AX protein than did SV-
HUC-V cells under chemical carcinogen MCA treatment1814(Figure 3B). This suggests less DNA damage under BBN or
MCA challenges in the benign urothelium that lost AR,
because p53, a known tumor suppressor involved in DNA
repair signaling and p53 deﬁciency, has been linked to bladder
tumorigenesis.22We then examined p53 expression in benign
urothelium and found that urothelium from Uro-AR/y mice
expressed a signiﬁcantly higher level of p53 than that from
Uro-ARþ/y mice (Figure 3C). We also found that expression
of PCNA, a key player in DNA excision repair23 that is up-
regulated by p53,24 was higher in urothelium from Uro-
AR/y mice thanUro-ARþ/y mice (Figure 3D). Together, data
from Figure 3, AeD, suggested that Uro-AR could modulateajp.amjpathol.org - The American Journal of Pathology
Figure 3 Increased expression of p53/PCNA signals resulted in less expression of the DNA damage marker g-H2AX in benign urothelium in Uro-AR/y mice.
After 12-weeks of BBN treatment, 20-week-old Uro-ARþ/y and Uro-AR/y mice were sacriﬁced, and bladders were harvested for histologic diagnosis. Benign
bladder tissues were selected for further examination of DNA damageerelated signals via IHC staining. A: Uro-ARþ/y benign urothelium expressed more
g-H2AX than did Uro-AR/y urothelium, indicating more DNA damage in Uro-ARþ/y urothelium (positive signal indicated by arrowheads). B: Western blot
analysis demonstrated that SV-HUC-AR stable cells expressed a higher a level of DNA damage marker g-H2AX than did SV-HUC-V stable cells after 1 and 2 hours
of treatment with the carcinogen MCA. C: Uro-AR/y urothelium expressed more p53 than did ARþ/y urothelium. p53 is well-known as a tumor suppressor
involved in DNA damage repair signaling (PZ 0.007; nZ 5). D: Uro-AR/y urothelium expressed more PCNA than did ARþ/y (P < 0.001; nZ 5). In normal
cells, PCNA serves as a DNA excision repair protein that is up-regulated by p53. For statistical analysis, differences in mean values between the 2 groups were
analyzed using the two-tailed t-test. Original magniﬁcation: 400 (A, C, and D). Scale bars: 50 mm (A, C, and D).
Urothelial AR Promotes BCa Developmentp53/PCNA signals to regulate DNA damage resulting in
promotion of bladder tumorigenesis.
Uro-AR Fails to Promote Bladder Tumorigenesis in
Uro-SV40T-AR/y Mice Lacking Active p53
To conﬁrm that Uro-AR promotes bladder tumorigenesis
through modulation of p53, we further tested the roles of Uro-
AR in mice lacking active p53. We generated Uro-ARKO
male mice harboring transgene UPII-SV40T (Uro-SV40T-
AR/y) (the detailed mating strategy and conﬁrmation are
shown in Supplemental Figure S2), in which SV40T antigen
is driven by the uroplakin II promoter. UPII-SV40T trans-
gene mice can develop urothelial carcinoma in situ due to
inactivated p53 and Rb by binding to SV40T antigen.25
We then examined bladder tumorigenesis in both Uro-
SV40T-ARþ/y and Uro-SV40T-AR/y mice at the ages of 15,
20, and 30weeks and found a 100% incidence of carcinoma in
situ at all three ages in both genotypes of mice (Figure 4A).
The histologic morphologic features of carcinoma in situ
in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice were
examined via H&E staining (Figure 4B). Furthermore, IHC
staining showed little difference in p53 expression between
tumors in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice
(Figure 4C). These results suggest that Uro-AR is not able to
promote bladder tumorigenesis in mice lacking active p53.
This conclusion was further conﬁrmed in the in vitro
neoplastic transformation assay. Adding p53 inhibitor PFT
during the process of neoplastic transformation of SV-HUC-V
andSV-HUC-ARcells led to little difference in colonynumbers
in soft agar, suggesting that loss of active p53 (via p53 inhibitor
PFT) abolishes AR-promoted colony formation (Figure 4D).The American Journal of Pathology - ajp.amjpathol.orgTogether, results from in vivo mouse models that lack
active p53 (Figure 4, AeC) and the in vitro neoplastic
transformation assay containing p53 inhibitor (Figure 4D)
suggest that the presence of p53 is necessary for Uro-AR to
promote bladder tumorigenesis.
Uro-AR Promotes BBN-Induced BCa Development
through Modulation of p53-p21
To further study the roles of Uro-AR in BCa development
after tumorigenesis, we evaluated BCa development in Uro-
ARþ/y and Uro-AR/y mice at age 30 weeks. Bladder tumors
(at stages pTa-pT1) were grossly identiﬁed in all Uro-ARþ/y
and Uro-AR/y mice. IHC staining showed a higher index of
proliferation marker PCNA in bladder tumors developed in
Uro-ARþ/y than those found in Uro-AR/y mice (Figure 5A),
which suggests that Uro-AR promotes cell proliferation in
bladder tumors.We further detected higher expression of p21,
a cell cycle modulator that controls cell proliferation and is
up-regulated by p53, in BCa developed in Uro-AR/y mice as
compared with Uro-ARþ/y mice (Figure 5B). We also
examined cell apoptosis in the tumors via TUNEL assay and
found a higher apoptotic index in Uro-AR/y mice compared
with ARþ/y mice (Figure 5C). This cell apoptotic result is
similar to that of an earlier study26 that found that p53
expression level is positively associated with apoptosis in
urothelial cells.
The results of Uro-AReregulated cell proliferation and
apoptosis of bladder tumors through p53 signals were
further conﬁrmed in the tumors (carcinoma in situ) of Uro-
SV40T-ARþ/y mice and Uro-SV40T-AR/y mice at age 20
weeks. The results showed little difference in either PCNA1815
Figure 4 AR fails to regulate bladder tumorigenesis by inactivatingp53.A:
BCa incidence in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice at various ages.
There was no difference in BCa incidence at age 30 (nZ 6), 20 (nZ 5), and 15
(nZ 3) weeks. In all Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice, the inci-
dence of BCawas 100%ofBCa at the three time points.B: Morphologic features
of BCa in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice at age 20 weeks. Both
genotypes of mice revealed carcinoma in situ. C: Detection of p53 expression in
urothelium of Uro-SV40T-ARþ/y and Uro-SV40T-AR/y mice at age 20 weeks.
Tumors in both genotypes of mice expressed similar levels of p53. D: Colony
formation assay of SV-HUC-V and SV-HUC-AR stable cells with PFT treatment
during neoplastic transformation. The results showed no statistical difference
in colony numbers between these two stable cells by adding p53 inhibitor.
Results are expressed as the means  SEM of three experiments. Original
magniﬁcation, 400 (B and C). Scale bars: 50 mm (B and C).
Figure 5 Uro-AR regulates BCa tumor growth through p53.A: Detection of
PCNA in bladder tumors of Uro-ARþ/y and Uro-AR/y mice. PCNA is a cellular
proliferationmarker. The results showed thatUro-ARþ/y bladder tumors express
more PCNA (PZ 0.015; nZ 4). B: Detection of p21 in bladder tumors of Uro-
ARþ/y and Uro-AR/y mice. Uro-AR/y tumors revealed signiﬁcantly more p21
(arrowheads) thandidUro-ARþ/y (PZ0.005;nZ4). p21 canbeup-regulated
by p53, promote cell cycle arrest, and serve as a tumor-suppressor gene. C:
TUNEL assay for apoptosis in Uro-ARþ/y and Uro-AR/y bladder tumors. Uro-
AR/y tumors revealed signiﬁcantly less apoptosis (PZ 0.004; nZ 4). Green
spots represent the apoptosis signal. D: Detection of the cell proliferation
marker PCNA in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y bladder tumors during
IHC staining, with no statistical difference in PCNA expression between Uro-
SV40T-ARþ/y and Uro-SV40T-AR/y tumors (PZ 0.924; nZ 5). E: TUNEL assay
for apoptosis in Uro-SV40T-ARþ/y and Uro-SV40T-AR/y tumors. No statistical
difference in apoptosis was found between Uro-SV40T-ARþ/y and Uro-SV40T-
AR/y tumors (PZ 0.240; nZ 5). For statistical analysis, differences in mean
values between the two groups were analyzed using the Student’s t-test.
Original magniﬁcation: 400 (AeE). Scale bars: 50 mm (AeE)
Hsu et alexpression (Figure 5D) or apoptotic index (Figure 5E)
between tumors of Uro-SV40T-ARþ/y and Uro-SV40T-
AR/y mice. Together, we provided in vivo evidence that
functional p53 activity is required for Uro-AR to regulate
BCa development.1816Increased Survival Rate in BBN-Treated Mice Lacking
Uro-AR
The consequence of Uro-AR promoting BBN-induced BCa
development was demonstrated by the decreased survival
rate in Uro-ARþ/y mice as compared with Uro-AR/y mice
(Figure 6). Considered together, our data indicate that Uro-ajp.amjpathol.org - The American Journal of Pathology
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Figure 6 Increased survival rate inmice lackingUro-ARwith BBN-induced
BCa. At age 6 weeks, male Uro-ARþ/y mice (nZ 22) and Uro-AR/y mice (nZ
11) were initially given drinking water containing BBN for 12 weeks. Mice
survival data were recorded weekly. The urinary tract organs (kidney, ureters,
bladder, and urethra) from deceased mice were harvested for diagnosis of
cause of death. The results showed that male Uro-AR/y mice had higher
survival rates than did male ARþ/y mice (100% versus 50%). The difference in
survival rate was analyzed using the log-rank (Mantel-Cox) test.
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Figure 7 Suppression of bladder tumorigenesis by the AR degradation
enhancer ASC-J9. A: Reduced bladder tumorigenesis in male mice using
ASC-J9 via i.p. injection. Twenty FVB male mice were subjected to BBN
treatment for 12 weeks to induce BCa. As soon as the ﬁrst mouse was found
to have hematuria (<50 erythrocytes/mL blood), all mice were subjected to
daily i.p. injection of vehicle or ASC-J9 (75 mg/kg body weight; n Z 10).
The results showed that mice given ASC-J9 had a signiﬁcantly lower inci-
dence of BCa than did mice given vehicle (20% versus 80%; P Z 0.023).
Difference in tumor incidence between the two groups was analyzed using
Fisher’s exact test. B: ASC-J9 had no effect on body weight of mice after 8
weeks of treatment. Body weight was measured at ages 16 and 24 weeks.
There was no difference in body weight between the control and ASC-J9
groups at age 16 or 24 weeks. The difference in mean body weight
between the two groups was analyzed using the two-tailed Student’s t-test.
Urothelial AR Promotes BCa DevelopmentAR promoted bladder tumorigenesis and that cancer
progression resulted in higher mortality in the BBN-induced
BCa mouse model.
Approach to Suppress BCa Development via AR
Degradation Enhancer ASC-J9
Our data revealed that Uro-AR/y mice exhibited a lower
incidence of carcinogen-induced BCa than did their WT
littermates, which suggests that Uro-AR promotes bladder
tumorigenesis. Therefore, targeting Uro-AR using anti-AR
molecules could be a potential approach to suppress BCa
development. To mimic the clinical conditions of BCa, we
ﬁrst administered ASC-J9 in mice via daily i.p. injection of
BBN-induced BCa (75 mg/kg body weight) at the ﬁrst sign
of hematuria and continued until the mice were aged
24 weeks. The results revealed that ASC-J9etreated mice
demonstrated a signiﬁcantly lower incidence of BCa than
did vehicle controletreated mice (20% versus 80%)
(Figure 7A). We also observed that ASC-J9 treatment had
little effect on serum testosterone concentration (data not
shown) and body weight as compared with vehicle control
treatment (Figure 7B). These results suggested that targeting
AR via ASC-J9 could be a novel approach to treat BCa at an
early stage of cancer progression.
Discussion
Multiple cells are involved in the BCa microenvironment,
including urothelial cells, ﬁbroblast cells, smooth muscle
cells, and inﬁltrating immune cells. More than 90% of
bladder tumors are derived from urothelium. Finding the
role of Uro-AR in promoting bladder tumorigenesis and
targeting AR with ASC-J9, leading to suppression of BCa at
an early developing stage, provide new insights that should
help reduce BCa progression and increase survival rates.
However, Uro-AR promotes bladder tumorigenesis and later
progression through modulation of p53, and an early reportThe American Journal of Pathology - ajp.amjpathol.orghas suggested that more than 50% of high-grade invasive
BCa tumors contain dysfunctional p53.27 Therefore, such
a therapeutic approach targeting Uro-AR may yield more
profound effects if administered in the stages of none
muscle invasive BCa, which contains more functional p53
expression. Furthermore, as early studies have suggested
that recurrence of BCa might be associated with expression
of Uro-AR,12 it will be beneﬁcial if additional clinical
studies prove targeting Uro-AR via ASC-J9 leads to
suppression of BCa recurrence.
Our results suggest that the dominance of Uro-AR in BCa
is due to modulation of p53 activity. Loss of p53 function
has been associated with bladder tumorigenesis and BCa
progression. For bladder tumorigenesis, Ozaki et al28 have
reported that p53-positive and p53-negative knockout mice
have a higher incidence of BBN-induced BCa than do WT
mice. In addition, Gao et al22 have suggested that p53
deﬁciency synergizes with activated Ha-ras in promoting
bladder tumorigenesis. For BCa progression, both grade and1817
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Figure 8 Mechanisms by which Uro-AR regulates bladder tumorigenesis
and BCa development. In benign bladder tissues, Uro-AR promotes the
carcinogen-induced DNA damage signal (g-H2AX) by suppressing p53 and
its downstream PCNA expression, which contributes to DNA damage repair.
This accumulated DNA damage is thought to contribute to later tumori-
genesis. After bladder tissues become malignant, Uro-AR also promotes
tumor growth by suppressing p53, thereby preventing downstream acti-
vation of p21, which normally induces cell cycle arrest. Suppression of p53
also inhibits cell apoptosis. Uro-AR promotes tumor growth and causes
death of the animal due to obstruction of the urinary tract.
Hsu et alstage of BCa have been associated with the mutation of
p53.29,30 These results also explain why AR has a consistent
role in promoting bladder tumorigenesis and BCa progres-
sion, because AR can regulate p53 activities in both normal
and neoplastic urothelium.
The mechanism by which Uro-AR negatively regulates p53
activity was not examined in our study. However, earlier
reports provide two mechanisms that may support our
conclusion. Nantermet et al31 indicated that p53 activity is
negatively regulated by AR activation without changing p53
RNA level. Experiments from prostate cancer (PCa) LNCaP
cells indicate that AR suppresses accumulation of p53 in the
nucleus, which suggests that AR may negatively regulate p53
activity through a posttranscriptional mechanism. Beitel et al32
indicated that the AR N-terminal transactivaton domain can
interact with PIRH2 (p53-induced RING-H2 protein), a p53-
induced ubiquitin-protein, which promotes p53 degrada-
tion.33 Lin et al34 also indicated that suppressingARvia siRNA
induces p53 protein expression through PIRH2 and further
promotes downstream p21 expression and results in increased
apoptosis, which provides the other mechanism in which AR
suppresses p53 activity through ubiquitin-induced protein
degradation.
CD24, a glycosyl phosphatidylinositol-linked sialoglyco-
protein, has been associated with urothelial carcinoma and
contributes to BCa progression.35,36 That the mechanism by
which CD24 mediates BCa development may be through
androgen/AR signaling was further suggested by Overdevest
et al,37 who used the BBN-induced cancer model with CD24-
deﬁcient male mice to demonstrate that such mice have
a lower incidence of bladder tumor and delayed bladder
malignancy, including metastasis and death. In the molecular
mechanical dissection, they found that CD24 mRNA and
protein expression are androgen dependent and that AR1818activation can induce CD24 promoter activity in human BCa
cell lines. The in vivo results of Overdevest et al37 are
consistent with our ﬁnding in Uro-ARKO mice, both of
which suggested that AR is involved in bladder tumorigen-
esis, cancer progression, and mortality. This conclusion
provides a solid rationale for BCa treatment that targets AR.
Uro-AR had positive roles in promoting both bladder
tumorigenesis and tumor progression,whichwas in apposition
to early ﬁndings that showed dual yet opposing roles of AR in
PCa38,39 and hepatocellular carcinoma.40 In PCa, AR func-
tions as a proliferator in PCa stroma cells, a survivor in PCa
luminal epithelial cells, and a suppressor in PCa basal
epithelial cells.38,39 In hepatocellular carcinoma, AR was
found to promote tumorigenesis,40 yet functioned as
a suppressor for hepatocellular carcinomametastasis,41 which
could be due to different intracellular signals in the same
hepatocytes at various stages.41 In the present study, we
found that Uro-AR had a consistent role in promoting BCa
progression at tumorigenesis and tumor progression, which
could be due to suppression of p53 expression or function.
In a previous study,12 we showed that the urothelium of
general ARKO mice implanted with dihydrotestosterone
pellets has signiﬁcantly higher apoptotic signals than does
that of WT mice after BBN treatment. This result provides
evidence that lacking AR in the urothelium can promote
BBN-induced cell apoptosis (Figure 5C). It has been re-
ported that p53 activity is negatively regulated by AR
activation31 and that p53 can induce BAX activation, which
promotes cell apoptosis.42 Therefore, we speculate that the
possible mechanism behind the data in Figure 5C is that lost
or decreasing AR expression in urothelium induces p53
activation, which promotes urothelial apoptosis through p53
downstream target genes such as Bax. An earlier study also
suggested that apoptosis may be closely associated with
carcinogenesis and tumor invasion of the rat bladder
induced by BBN,43 which supports the data in Figure 5C.
Umbrella cells are the ﬁrst lining layer of urothelial cells,
which directly contacts with urine in the bladder lumen.
Therefore, umbrella cells have a higher risk of being
exposed to urinary carcinogens. Indeed, urinary carcinogens
are associated with the risk of BCa.44e47 In the present
study, the major urinary metabolite of BBN was BCPN.48
After a-hydroxylation, BCPN chemically induced DNA
alkylation on urothelial cells49 and resulted in phosphory-
lation of H2AX.50 Therefore, our data (Figure 3) suggest
that g-H2AX signals shown in umbrella cells may be due to
direct exposure to BCPN in the urine. Furthermore, not all
bladder tumors derive from basal cells. Cytokeratin 20, an
umbrella cell marker, has been reliably observed in the
primary tumor and its matched lymph node metastasis.51
p63 is a member of the p53 family, which encodes
multiple products with transactivating, death-inducing, and
dominant-negative activities,52 and Guo et al53 have sug-
gested that p63 could induce senescence and suppress
tumorigenesis in vivo. Moreover, a clinical report has also
indicated that altered expression of p63 is associated withajp.amjpathol.org - The American Journal of Pathology
Urothelial AR Promotes BCa Developmenthuman BCa.54 We have used IHC staining to examine the
p63 protein expression on the normal urothelium of wild-type
and Uro-ARKO mice at age 20 weeks after BBN treatment.
The results showed that p63 protein expression level is
signiﬁcantly higher in Uro-ARKO mouse urothelium than in
WT mouse urothelium (Supplemental Figure S3), whereas
Uro-ARKO mice have a lower rate of bladder cancer than do
WT mice (Figure 1B). Therefore, our results suggest that
elevated p63 expression in Uro-ARKO urothelium is asso-
ciated with a lower incidence of BCa. This conclusion is
consistent with the references described previously.
In summary, usingmultiple in vitro and in vivo approaches,
our results demonstrate that Uro-AR consistently promotes
bladder tumorigenesis, tumor progression, and animal death.
We further dissected the mechanisms by which Uro-AR
regulates BCa development through p53 (Figure 8). The
present study revealed that AR degradation enhancer ASC-J9
could substantially suppress bladder tumorigenesis in
a carcinogen-induced BCamouse model, which suggests that
Uro-AR is a potential target against BCa.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.01.018.
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